Retinal ganglion cell loss in neuromyelitis optica: a longitudinal study
- PMID: 29921610
- DOI: 10.1136/jnnp-2018-318382
Retinal ganglion cell loss in neuromyelitis optica: a longitudinal study
Abstract
Objectives: Neuromyelitis optica spectrum disorders (NMOSD) are inflammatory conditions of the central nervous system and an important differential diagnosis of multiple sclerosis (MS). Unlike MS, the course is usually relapsing, and it is unclear, if progressive neurodegeneration contributes to disability. Therefore, we aimed to investigate if progressive retinal neuroaxonal damage occurs in aquaporin4-antibody-seropositive NMOSD.
Methods: Out of 157 patients with NMOSD screened, 94 eyes of 51 patients without optic neuritis (ON) during follow-up (F/U) and 56 eyes of 28 age-matched and sex-matched healthy controls (HC) were included (median F/U 2.3 years). The NMOSD cohort included 60 eyes without (EyeON -) and 34 eyes with a history of ON prior to enrolment (EyeON+). Peripapillary retinal nerve fibre layer thickness (pRNFL), fovea thickness (FT), volumes of the combined ganglion cell and inner plexiform layer (GCIP) and the inner nuclear layer (INL) and total macular volume (TMV) were acquired by optical coherence tomography (OCT).
Results: At baseline, GCIP, FT and TMV were reduced in EyeON+ (GCIP p<2e-16; FT p=3.7e-4; TMV p=3.7e-12) and in EyeON - (GCIP p=0.002; FT p=0.040; TMV p=6.1e-6) compared with HC. Longitudinally, we observed GCIP thinning in EyeON- (p=0.044) but not in EyeON+. Seven patients had attacks during F/U; they presented pRNFL thickening compared with patients without attacks (p=0.003).
Conclusion: This study clearly shows GCIP loss independent of ON attacks in aquaporin4-antibody-seropositive NMOSD. Potential explanations for progressive GCIP thinning include primary retinopathy, drug-induced neurodegeneration and retrograde neuroaxonal degeneration from lesions or optic neuropathy. pRNFL thickening in the patients presenting with attacks during F/U might be indicative of pRNFL susceptibility to inflammation.
© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.
Conflict of interest statement
Competing interests: FCO has nothing to disclose. JH reports personal fees and non-financial support from Merck, grants, personal fees and non-financial support from Novartis, personal fees from Roche, non-financial support from Bayer Healthcare, personal fees from Santhera, personal fees and non-financial support from Biogen, personal fees and non-financial support from Sanofi Genzyme, all outside the submitted work. ARF is sponsored by Abide Therapeutic outside of the submitted work and reports no potential conflicts of interest. NL has nothing to disclose. HZ reports grants from Novartis, during the conduct of the study. SM has nothing to disclose; he is named as inventor on a patent application describing OCT image analysis. NB has nothing to disclose. JBS received speaking fees and travel grants from Bayer Healthcare, Sanofi-Aventis/Genzyme, Biogen and Teva Pharmaceuticals, unrelated to the present scientific work. PA reports grants, personal fees and non-financial support from Allergan, personal fees and non-financial support from Bayer Healthcare, grants, personal fees and non-financial support from Biogen, grants, personal fees and non-financial support from Ipsen, grants, personal fees and non-financial support from Merz Pharmaceuticals, personal fees and non-financial support from Merck, grants, personal fees and non-financial support from Novartis, non-financial support from Sanofi-Aventis/Genzyme, personal fees and non-financial support from Teva Pharmaceuticals, grants, personal fees and non-financial support from Roche, outside the submitted work. KR reports research support from Novartis and Merck Serono as well as speaking fees or travel grants from Bayer Healthcare, Biogen Idec, Merck Serono, Sanofi-Aventis/Genzyme, Teva Pharmaceuticals, Roche, Novartis and the Guthy-Jackson Charitable Foundation, all unrelated to this work. TK received travel expenses and personal compensations from Bayer Healthcare, Teva Pharmaceuticals, Merck, Novartis Pharma, Sanofi-Aventis/Genzyme, Roche and Biogen as well as grant support from Bayer-Schering AG, Novartis and Chugai Pharma, unrelated to this work. OW has nothing to disclose. SJ has nothing to disclose. MIL reports personal fees from Biogen Idec and grants from Novartis, outside the submitted work. JP reports grants Journal of Neurology, Neurosurgery and Psychiatry and personal fees from Merck Serono, grants and personal fees from Biogen Idec, personal fees from Teva Pharmaceuticals, grants from Chugai, grants and personal fees from MedImmun, grants and personal fees from Alexion, grants and personal fees from Novartis, personal fees from Roche, grants from Genzyme, grants and personal fees from ABIDE, personal fees from TG Therapeutics, outside the submitted work. In addition, JP has a patent Isis: Diagnosing Multiple Sclerosis. FP reports research grants and speaker honoraria from Bayer, Teva, Genzyme, Merck, Novartis, MedImmune and is member of the steering committee of the OCTIMS study (Novartis), all unrelated to this work. AUB is cofounder and holds shares of commercial entities Motognosis and Nocturne. He is named as inventor on several patent applications describing serum biomarkers for MS, perceptive visual computing for tracking of motor dysfunction and OCT image analysis.
Similar articles
-
Retinal Optical Coherence Tomography in Neuromyelitis Optica.Neurol Neuroimmunol Neuroinflamm. 2021 Sep 15;8(6):e1068. doi: 10.1212/NXI.0000000000001068. Print 2021 Nov. Neurol Neuroimmunol Neuroinflamm. 2021. PMID: 34526385 Free PMC article.
-
Thickness of macular inner retinal layers and peripapillary retinal nerve fibre layer in neuromyelitis optica spectrum optic neuritis and isolated optic neuritis with one episode.Acta Ophthalmol. 2017 Sep;95(6):583-590. doi: 10.1111/aos.13257. Epub 2016 Oct 24. Acta Ophthalmol. 2017. PMID: 27775238
-
Optical coherence tomography in myelin-oligodendrocyte-glycoprotein antibody-seropositive patients: a longitudinal study.J Neuroinflammation. 2019 Jul 25;16(1):154. doi: 10.1186/s12974-019-1521-5. J Neuroinflammation. 2019. PMID: 31345223 Free PMC article.
-
A comparative study of alteration in retinal layer segmentation alteration by SD-OCT in neuromyelitis optica spectrum disorders: A systematic review and meta-analysis.Adv Ophthalmol Pract Res. 2021 Oct 5;1(1):100007. doi: 10.1016/j.aopr.2021.100007. eCollection 2021 Nov. Adv Ophthalmol Pract Res. 2021. PMID: 37846392 Free PMC article. Review.
-
Optical Coherence Tomography and Magnetic Resonance Imaging in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder.Int J Mol Sci. 2016 Nov 15;17(11):1894. doi: 10.3390/ijms17111894. Int J Mol Sci. 2016. PMID: 27854301 Free PMC article. Review.
Cited by
-
Optic chiasm measurements may be useful markers of anterior optic pathway degeneration in neuromyelitis optica spectrum disorders.Eur Radiol. 2020 Sep;30(9):5048-5058. doi: 10.1007/s00330-020-06859-w. Epub 2020 Apr 26. Eur Radiol. 2020. PMID: 32335748 Free PMC article.
-
NMOSD IgG Impact Retinal Cells in Murine Retinal Explants.Curr Issues Mol Biol. 2023 Sep 7;45(9):7319-7335. doi: 10.3390/cimb45090463. Curr Issues Mol Biol. 2023. PMID: 37754247 Free PMC article.
-
The Role of Optical Coherence Tomography in Differential Diagnosis of Multiple Sclerosis and Autoimmune Connective Tissue Diseases with CNS Involvement.J Clin Med. 2020 May 21;9(5):1565. doi: 10.3390/jcm9051565. J Clin Med. 2020. PMID: 32455833 Free PMC article.
-
Visual quality of life in NMOSD and MOGAD: profiles, dynamics and associations with ageing and vision.J Neurol. 2024 Dec 21;272(1):86. doi: 10.1007/s00415-024-12803-5. J Neurol. 2024. PMID: 39708205
-
Optical coherence tomography angiography indicates subclinical retinal disease in neuromyelitis optica spectrum disorders.Mult Scler. 2022 Apr;28(4):522-531. doi: 10.1177/13524585211028831. Epub 2021 Jul 14. Mult Scler. 2022. PMID: 34259579 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous